A Message From Our Program Leader
At HonorHealth, we recognize that a pancreatic cancer diagnosis can be life-changing. That’s why our team is committed to delivering the most advanced, compassionate, and personalized care available. From early detection to treatment, our multidisciplinary experts work together to support you every step of the way.
We’re also proud to be at the forefront of pancreatic cancer research and drug development. Our team is leading groundbreaking clinical trials and innovative therapies designed to improve outcomes and offer new hope. Every patient is screened for clinical trial eligibility, ensuring access to the latest advancements in care. These efforts reflect our mission: to bring tomorrow’s treatments to patients today—because you deserve nothing less.
About Our Program
At HonorHealth, patients with pancreatic cancer benefit from truly comprehensive, coordinated care delivered by a team of dedicated specialists. Your care team may include experts in surgery, gastroenterology, radiology, medical and radiation oncology, pathology, and other key disciplines—all working together to support your unique needs. These specialists meet weekly at a pancreatic tumor board to review your case in detail and develop a personalized treatment plan tailored specifically to you. In addition to medical expertise, you’ll also have access to nutrition counseling, social work support, and spiritual care services, ensuring that every aspect of your well-being is addressed. This collaborative, patient-centered approach is designed to provide compassionate care and the best possible outcomes
Pancreatic Research Cancer Facts and Figures
Pancreatic ductal adenocarcinoma, commonly known as pancreatic cancer, is the third-leading cause of cancer death in the U.S., and rates continue to rise, according to the CDC.
HonorHealth sees over 250 new consults of pancreatic cancer patients yearly.
Among HRI’s most significant contributions is the advancement of pancreatic cancer treatment. This includes its pivotal work on nab-paclitaxel combined with gemcitabine, now a standard first-line regimen, and the development of Onivyde, the first approved second-line therapy for pancreatic cancer, which improved survival without compromising quality of life. HRI was also the first to trial the triple combination of gemcitabine, nab-paclitaxel, and cisplatin, a regimen recently added to the NCCN guidelines, further validating its clinical impact.
Pancreatic Cancer Clinical Trials
Since its launch in 2005, HonorHealth’s cancer research program has established strong partnerships with leading universities, nonprofit organizations and medical device and drug companies. With a proven track record of advances in diagnosing and treating pancreatic cancer, HonorHealth Cancer Care in the greater Phoenix area can give you personalized care – from diagnosis through treatment.